← Leaderboards
Campbell McInnes
University Of South Carolina At Columbia
$4,163,162
Attributed
$4,352,979
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $598.4K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,352,979 · 9
By mechanism
R01$1,418,279 · 1
R41$845,555 · 3
P20$815,060 · 1
R21$725,451 · 2
P30$405,388 · 1
R03$143,246 · 1
Top collaborators
- Michael D Wyatt2 shared
Most similar at University Of South Carolina At Columbia
Same institution · by research overlap
- Michael D Wyatt$3,777,677
- Michael A Matthews$643,887
- John W Weidner$985,122
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignPharmaceutical PreparationsStructureLigandsSiteBaseIn VitroDrug DiscoveryPeptidesProteinsPharmaceutical ChemistryProtein Protein InteractionTumorMalignant NeoplasmsDrug KineticsSmall MoleculeCellsPropertyMediatingInhibitor/AntagonistBindingPhosphorylationLinkAntitumor Drug
Grant awards (22)
Investigating Abbapolin PLK1 Polo Box Domain inhibitors as potential therapeutics for colorectal cancers$395,724
R41 · FY2025 · CA · contact PI
Drug Design and Synthesis Core$202,694
P30 · FY2025 · GM · contact PI
Drug Design and Synthesis Core$202,694
P30 · FY2024 · GM · contact PI
Drug Design and Synthesis Core$154,389
P20 · FY2023 · GM · contact PI
Development of non-ATP competitive chemical biology probes to elucidate mechanisms of PLK1 activation and stability.$170,662
R21 · FY2022 · CA · contact PI
Drug Design and Synthesis Core$168,971
P20 · FY2022 · GM · contact PI
Development of non-ATP competitive chemical biology probes to elucidate mechanisms of PLK1 activation and stability.$208,973
R21 · FY2021 · CA · contact PI
Drug Design and Synthesis Core$163,900
P20 · FY2021 · GM · contact PI
Drug Design and Synthesis Core$163,900
P20 · FY2020 · GM · contact PI
Drug Design and Synthesis Core$163,900
P20 · FY2019 · GM · contact PI
Novel Chemical Biology Probes based on Selective Inhibitors of the Polo-Box Domain of PLK1$71,623
R03 · FY2018 · CA · contact PI
Polo-box PLK1 Inhibitors Target Tumors Resistant to ATP Competitive Compounds$224,933
R41 · FY2017 · CA · contact PI
Inhibitors of B-raf through the Dimerization Interface$182,832
R21 · FY2017 · CA · contact PI
Novel Chemical Biology Probes based on Selective Inhibitors of the Polo-Box Domain of PLK1$71,623
R03 · FY2017 · CA · contact PI
Inhibitors of B-raf through the Dimerization Interface$162,984
R21 · FY2016 · CA · contact PI
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics$224,898
R41 · FY2014 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$273,424
R01 · FY2012 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$272,007
R01 · FY2011 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$280,420
R01 · FY2010 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$284,413
R01 · FY2009 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$9,588
R01 · FY2009 · CA · contact PI
Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R$298,427
R01 · FY2008 · CA · contact PI